Pinaverium bromide 100 mg
Dimeticone 300 mg
A treatment with triple action mechanism (antispasmodic and regulator of intestinal flatulence), indicated in irritable bowel syndrome (IBS) characterized by abdominal pain or discomfort (visceral hyperalgesia and allodynia) in disorders associated with the frequency or consistency of bowel movements in any of its variants (constipation predominant, diarrhea-predominant or alternating constipation diarrhea), irritable bowel syndrome, nervous colitis, functional colopathies.
DOSAGE AND ADMINISTRATION:
The usual drug treatment for patients with irritable bowel syndrome in any of its variants "diarrhea-predominant", "constipation predominant" or "alternate" usually required for adequate control of the symptoms a dose of one capsule of ALEVIAN DUO ® twice a day, 10-15 minutes before breakfast and lunch. Some severe or difficult to cases, may require to increase the dose to one capsule three times a day.
Patients with irritable bowel syndrome (IBS) have regulatory mechanisms of gastrointestinal motility altered in the presence of the lipid components of the diet. This results in a state of hypersensitivity and dysfunction in the propulsion of intraluminal gas, so it is advisable to instruct the patient about the advantages of restricting dietary fat intake to no more than 20% of the daily dietary composition.
Hypersensitivity to the components of the formula.
RESTRICTIONS OF USE DURING PREGNANCY AND BREASTFEEDING:
Both pinaverium bromide as dimeticone are active ingredients with poorly absorbed into the systemic circulation. However, since there is not enough clinical experience of its use during pregnancy and / or breastfeeding, ALEVIAN DUO ® should always be administered solely at the discretion of the treating physician, having established a rigorous risk analysis / benefit.
Pinaverium bromide, by its local effect, has a low incidence of side effects and adverse. However, there have been isolated cases of discomfort such as abdominal pain, itching, rash, regurgitation and dysphagia.
Meanwhile, to date there are no reported adverse reactions due to administration of dimeticone.
None reported to date for drug interactions pinaverium bromide and dimeticone.
OVERDOSE OR ACCIDENTAL INGESTION:
The data obtained from the toxicity studies pinaverium bromide and dimeticone not indicate any potential risk of toxicity for both compounds by overdosing. However, in the case of any event or episode of intake accidental or intentional overdose manifesting acute clinical data, it shall apply the life support cardiopulmonary brain-universally accepted standard for the management of poisoning.
Box with blister containing 32 soft gelatin capsules containing 100 mg of pinaverium bromide and 300 mg of dimeticone.
Store at room temperature to not more than 30 ° C and in a dry place.
Keep out of reach of children.
NYCOMED, S.A. de C.V.